Oppenheimer & Co’s Ironwood Pharmaceuticals IRWD Stock Holding History

Oppenheimer & Co’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-40,596	Closed	-$525K	–	1364
2018 Q1	$525K	Hold	40,596	–	–	0.01%	833
2017 Q4	$510K	Hold	40,596	–	–	0.01%	855
2017 Q3	$536K	Buy	40,596 +4,298	+12%	+$59.1K	0.01%	820
2017 Q2	$574K	Hold	36,298	–	–	0.02%	786
2017 Q1	$519K	Hold	36,298	–	–	0.01%	782
2016 Q4	$465K	Sell	36,298 -477	-1%	-$6.03K	0.01%	838
2016 Q3	$489K	Buy	36,775 +955	+3%	+$11.2K	0.01%	823
2016 Q2	$392K	Buy	+35,820	New	+$350K	0.01%	875
2015 Q4	–	Sell	-147,184	Closed	-$1.28M	–	1321
2015 Q3	$1.28M	Sell	147,184 -49,110	-25%	-$458K	0.04%	499
2015 Q2	$1.98M	Buy	+196,294	New	+$2.28M	0.06%	401

Other funds holding IRWD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co's IRWD Position: Q2 2018 in Review

Oppenheimer & Co sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2018, closing a stake of 40,596 shares — an estimated $525K sold.

Oppenheimer & Co first reported a position in IRWD in Q2 2015 and held it in 10 quarters. The position peaked at $1.98M in Q2 2015. 148 funds tracked by Wall St. Rank hold IRWD as of Q2 2018.

Oppenheimer & Co reported no remaining Ironwood Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Oppenheimer & Co sold 40,596 Ironwood Pharmaceuticals shares in Q2 2018, an estimated $525K.
Oppenheimer & Co first reported a position in Ironwood Pharmaceuticals in Q2 2015 and held it in 10 quarters.
Oppenheimer & Co's Ironwood Pharmaceuticals position peaked at $1.98M in Q2 2015.
148 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2018.

Based on Oppenheimer & Co's 13F filing for Q2 2018, filed 10 Aug 2018.